Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies

NCT02017613 is registered in ClinicalTrials.gov with Rhizen Pharmaceuticals SA as lead sponsor.

NCT NCT02017613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02017613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Lead sponsor
Rhizen Pharmaceuticals SA
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2013
Completion date
May 31, 2016
Enrollment
35 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell, t-cell lymphoma